ACE2 and COVID-19: In addition, interaction between SARS-CoV-2 and ACE2 may disturb the balance of the renin–angiotensin system and reduce ACE2 availability, which in turn increases angiotensin II activity, promoting vasoconstriction, inflammation and further cardiovascular damage in patients with COVID-19 [23].